The aml Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the aml Hub cannot guarantee the accuracy of translated content. The aml and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Astellas, Daiichi Sankyo, Johnson & Johnson, Kura Oncology and Syndax, and has been supported through educational grants from Bristol Myers Squibb and the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View aml content recommended for you
Mylotarg (gemtuzumab ozogamicin) given ‘positive opinion’ by the EMA CHMP for use in untreated CD33-positive AML
On 23 February 2018, the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) granted a positive opinion, recommending the approval of Mylotarg (gemtuzumab ozogamicin) in combination with daunorubicin and cytarabine for the treatment of patients aged 15 years and above with previously untreated de novo, CD33-positive Acute Myeloid Leukemia (AML), except Acute Promyelocytic Leukemia (APL).1 This positive opinion follows the recent U.S. Food and Drug Administration (FDA) approval of Mylotarg for newly diagnosed and relapsed/refractory CD33-positive AML on 4 September 2017, which was reported here.
Mylotarg, an Antibody Drug Conjugate (ADC), is an antibody-targeted chemotherapeutic agent consisting of a humanized murine CD33 antibody. Since it is a humanized anti-CD33 monoclonal antibody, it is highly specific for targeting leukemic blasts. Mylotarg binds to, and is internalized by tumor cells expressing CD33. As a result, this ADC can then dispense the anti-tumor antibiotic calicheamicin to CD33-expressing tumor cells.2
This recommendation of approval for Mylotarg by the EMA CHMP was based on results from the phase III randomized ALFA-0701 study (NCT00927498), which showed that the combination of Mylotarg with standard chemotherapy regimen in newly diagnosed de novo adult AML patients significantly improved 3-year Event Free Survival (EFS) and Relapse Free Survival (RFS) compared to chemotherapy alone.3
If Mylotarg is approved by the European Commission (EC), the drug manufacturers, Pfizer, highlighted that “the addition of Mylotarg to standard chemotherapy will provide an important new treatment option for patients with AML who would typically be treated with chemotherapy alone”.
References